Compare BC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | LQDA |
|---|---|---|
| Founded | 1845 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.5B |
| IPO Year | 1994 | 2020 |
| Metric | BC | LQDA |
|---|---|---|
| Price | $67.28 | $68.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $83.55 | $41.00 |
| AVG Volume (30 Days) | 717.1K | ★ 963.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 1.99 | 1.26 |
| Revenue | ★ $5,362,800,000.00 | $158,320,000.00 |
| Revenue This Year | $9.81 | $278.87 |
| Revenue Next Year | $5.11 | $57.13 |
| P/E Ratio | ★ $33.25 | $56.31 |
| Revenue Growth | 2.40 | ★ 1031.18 |
| 52 Week Low | $58.66 | $21.35 |
| 52 Week High | $90.25 | $93.61 |
| Indicator | BC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 47.51 |
| Support Level | N/A | $62.86 |
| Resistance Level | $84.63 | $92.35 |
| Average True Range (ATR) | 2.19 | 2.78 |
| MACD | -0.06 | 0.69 |
| Stochastic Oscillator | 23.23 | 66.74 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.